Available online on https://ijarms.com

International Journal of Advance Research in Medical Science 2025; 1(1):11-16

(Review Article)

Artificial Intelligence in Drug Management: A Review

Mahesh Kumar Sharma[1], Sagar Dattatray kore[2], Sachin Sharma[3]

[1]Associate Professor, Arya College of Pharmacy, Jaipur Rajasthan
[2]Assistant Professor, Siddhant College of Pharmacy, Pune, Maharashtra
[3]Associate Professor, Parul University, Vadodara, Gujarat

Received: 01/01/2025/ Revised: 13/02/2025/ Accepted: 15-03-2025
Corresponding Author: Dr. Mahesh Kumar Sharma
Conflict of interest: Nil

Abstract

Artificial intelligence (AI) has revolutionized many aspects of the pharmaceutical industry, including drug discovery and development, drug repurposing, improving pharmaceutical productivity, clinical trials, medication management, and drug delivery design. AI algorithms can analyze extensive biological data, including genomics and proteomics, to identify disease-associated targets and predict their interactions with potential drug candidates, enabling a more efficient and targeted approach to drug discovery. AI can also assist in experimental design, predict the pharmacokinetics and toxicity of drug candidates, and optimize research and development processes, reducing the need for extensive and costly animal testing. In pharmacy practice, AI technology has a wide range of applications, enabling pharmacists to make decisions based on current data, improving medication management, streamlining workflow, and enhancing patient safety and outcomes. AI can also assist pharmacies with inventory management, predict drug demand, and optimize inventory management, maintaining adequate stock levels and reducing waste. Despite its potential, the implementation of AI in pharmacies faces several challenges, including data quality, initial expense required for AI integration, and the need for comprehensive education and training.

Keywords: Artificial Intelligence, Drug Managements, Pharmaceutical Industry, Drug Development, and Drug Discovery.

INTRODUCTION

Chemical scientists and pharmaceutical companies conduct significant research in the area of drug design and development. Nonetheless, low viability, off-target conveyance, time utilization, and significant expense force an obstacle and difficulties that effect drug plan and revelation. Further, perplexing and enormous information from genetics studies, microarray information, and clinical preliminaries moreover force an obstruction in the medication disclosure pipeline. Man-made brainpower and AI innovation assume a pivotal part in drug revelation and improvement. [1] At the end of the day, fake brain organizations and profound learning calculations have modernized the region. Structure-based virtual screening, ligand-based virtual screening, toxicity prediction, drug monitoring and release, quantitative structure–activity relationship, drug repositioning, polypharmacology, and physiochemical activity are just a few of the drug discovery processes where machine learning and deep learning algorithms have been used. Proof from the past fortifies the execution of man-made reasoning and profound learning in this field. Additionally, cutting-edge methods for data management, curation, and mining aided recently developed modeling algorithms greatly. In outline, man-made reasoning and profound learning headways give a brilliant a chance for level headed medication plan and disclosure process. The essential concern related with drug plan and improvement is time utilization and creation cost. Further, inefficiency, incorrect objective conveyance, and unseemly dose are different obstacles that restrain the course of medication conveyance and advancement. With headways in innovation, PC helped drug configuration coordinating man-made reasoning calculations can dispose of the difficulties and obstacles of conventional medication plan and improvement. While machine learning consists of supervised learning, unsupervised learning, and reinforcement learning, artificial intelligence is referred to as a superset that includes machine learning. Further, profound learning, a subset of AI, has been widely executed in drug plan and improvement. The counterfeit brain organization, profound brain organization, support vector machines, characterization and relapse, generative ill-disposed networks, emblematic learning, and meta-learning are instances of the calculations applied to the medication plan and disclosure process. Computerized reasoning has been applied to various areas of medication plan and create ment process, for example, from peptide union to atom plan, virtual screening to sub-atomic docking, quantitative

structure-movement relationship to sedate repositioning, protein misfolding to protein cooperations, and sub-atomic pathway recognizable proof to polypharmacology. Man-made reasoning standards have been applied to the characterization of dynamic and latent, observing medication discharge, pre-clinical and clinical turn of events, essential and optional medication screening, biomarker development, pharmaceutical management, bioactivity, identification, and physiochemical properties, prediction of toxicity, And identification of acton . [3]

From the beyond twenty years, the improvement of effective and high level frameworks for the designated conveyance of helpful specialists with greatest effectiveness and least dangers has forced an extraordinary test among substance and natural researchers. Another obstacle in the drug design and development process was the time and money required to develop novel therapeutic agents. To limit these difficulties and obstacles, analysts around the globe pushed toward computational methodologies, for example, virtual screening (Versus) and sub-atomic docking, which are otherwise called customary methodologies. Notwithstanding, these techniques likewise force difficulties like error and inef-ficiency. Subsequently, there is a flood in the execution of novel strategies, which are independent to dispense with the difficulties experienced in customary computational approaches.[4] Computerized reasoning (simulated intelligence), including profound learning (DL) and AI (ML) calculations, has arisen as a potential arrangement, which can defeat problems and obstacles in the medication plan and disclosure process Also, drug disclosure and planning contain long and complex advances like objective choice and validation, restorative screening and lead compound streamlining, pre-clinical and clinical preliminaries, and assembling rehearses. These all means force one more monstrous test in the recognizable proof of viable prescription against an illness. Organizations is dealing with the expense and speed of the cycle. Artificial intelligence has responded to this multitude of inquiries in a basic and logical way, which diminished the time utilization and cost of the process. Besides, the expansion in information digitization in the drug organizations and medical services area spurs the execution of simulated intelligence to defeat the issues of scru- tinizing the complicated information. The capacity of computer systems to learn from input or previous data is referred to as AI, also known as machine intelligence. The term man-made intelligence is generally utilized when a machine impersonates mental way of behaving related with the human mind during learning and critical thinking. In today's drug design and discovery process, artificial intelligence (AI) algorithms are heavily incorporated by chemical and biological researchers. Computational demonstrating in light of computer based intelligence and ML standards gives an incredible road to ID and approval of substance compounds, target ID, peptide amalgamation, assessment of medication poisonousness and physiochemical properties, drug checking, drug adequacy and viability, and medication repositioning .With the coming of simulated intelligence standards along with ML and DL calculations, Versus of mixtures from chemical libraries, which involves in excess of 10 6 million compounds, become simple and time-compelling. Further, computer based intelligence model stake out the poisonousness issues. [8]

Artificial Intelligence and Big Data Play a Part in Revolutionizing the Drug Discovery Process

Enormous information can be characterized as informational indexes that are excessively huge and multifaceted to be broke down with the customary information investigating programming, instruments, and methods. The three primary person istic elements of enormous information are volume, speed, and assortment, where volume addresses the enormous sum and mass of information created, speed addresses the rate at which these informationare being duplicated, and assortment addresses heterogenicity present in the informational indexes. With the appearance of microbar beam, RNA-seq, and high-throughput sequencing (HTS) technologies, a plenty of biomedical information is being caused consistently, because of which contemporary medication disclosure has made a progress into the large information time. In drug revelation, the above all else step is the ID of appropriate targets (e.g., qualities, proteins) engaged with infection patho-physiology, trailed by finding reasonable medications or medication like particles which can interfere with these objectives, and presently we approach a group of stars of biomedical information stores which can help us in such manner. Also, the evolution of man-made intelligence has made enormous information investigation much more straightforward as there isa bunch of ML procedures accessible now, which can help in separating valuable highlights, examples, and designs present in these large biomedical informational indexes. To recognize the target distinguishing proof, a component such as a quality articulation is typically employed to understand illness instruments and locate attributes associated with the condition. Many challenges have yielded high-quality articulation information thanks to advancements in RNA-seq and microarray technologies. [9]

Assembly of AI Furthermore, Regular Science: Further Develops Drug Discovery

Artificial intelligence (AI) is significantly impacting drug discovery and development, offering the potential for lower costs and shorter development timelines. AI-enabled drug discovery has achieved several milestones, including the first AI-designed drug molecule to enter human clinical trials and the

generation of promising drug compounds from scratch. AI is revolutionizing various stages of the drug discovery process, such as target identification, molecular simulations, and prediction of drug properties. The use of AI tools is beginning to upend the drug discovery pipeline, with several new compounds entering clinical trials, and AI-designed drugs are being developed for both potential blockbuster status and neglected diseases. Despite the potential, the application of AI in drug discovery faces challenges, including the need for independent verification, data representation, labeling, privacy, ethical concerns, and model interpretations.[19]

Certainly! The assembly of Artificial Intelligence (AI) in conjunction with regular science, particularly in the field of drug discovery, has been instrumental in advancing pharmaceutical research and development. Here's how:

Data Analysis and Prediction:

AI algorithms can analyze vast amounts of biological and chemical data to identify potential drug candidates. This includes genomics, proteomics, and metabolomics data, as well as information from clinical trials and literature. AI can predict how different molecules will interact with biological targets, helping researchers narrow down their focus to the most promising compounds. Data analysis and prediction using artificial intelligence (AI) has significant potential in drug management, particularly in drug discovery and development, drug repurposing, improving pharmaceutical productivity, clinical trials, medication management, and drug delivery design. AI algorithms can analyze extensive biological data, including genomics and proteomics, to identify disease-associated targets and predict their interactions with potential drug candidates, enabling a more efficient and targeted approach to drug discovery. AI can also assist in experimental design, predict the pharmacokinetics and toxicity of drug candidates, and optimize research and development processes, reducing the need for extensive and costly animal testing. In pharmacy practice, AI technology has a wide range of applications, enabling pharmacists to make decisions based on current data, improving medication management, streamlining workflow, and enhancing patient safety and outcomes. AI can also assist pharmacies with inventory management, predict drug demand, and optimize inventory management, maintaining adequate stock levels and reducing waste. However, the implementation of AI in drug management faces challenges, including data quality, initial expense required for AI integration, and the need for comprehensive education and training. [20]

Drug Repurposing:

AI can sift through existing drugs and compounds to identify potential new uses for them. By analyzing molecular structures and biological pathways, AI algorithms can suggest existing drugs that may be effective in treating different diseases than they were originally intended for. This approach can significantly reduce the time and cost of drug development. [20]

AI-powered drug repurposing has several advantages, including:

- Reducing time and cost in drug development
- Lowering risk in the process of developing drugs for cancers and other rare illnesses
- Enabling a more productive approach in identifying new therapeutic uses for already-available drugs

Virtual Screening:

Instead of physically testing thousands of compounds in the lab, AI can conduct virtual screening to identify molecules with the highest likelihood of being effective drugs. By simulating molecular interactions, AI algorithms can quickly prioritize compounds for further testing, accelerating the drug discovery process. AI techniques such as machine learning from genomics and bioinformatics data, and mining of electronic medical records (EMR) and claims data can be deployed to cover everything from drug to protein interactions at the molecular level to sifting through millions of records to find existing drugs used to treat other conditions. The success of a virtual screen is defined in terms of finding interesting new scaffolds rather than the total number of hits. Interpretations of virtual screening accuracy should consider the finding of interesting new scaffolds rather than the total number of hits. [12]

Personalized Medicine:

AI can analyze individual patient data, such as genetic information and medical history, to identify the most effective treatments for specific individuals. This personalized approach to medicine has the potential to improve patient outcomes and reduce adverse reactions to drugs. Personalized medicine, also known as precision medicine, is an emerging approach that uses an individual's genetic profile to guide decisions related to the prevention, diagnosis, and treatment of disease. This practice leverages a patient's unique genetic makeup to help doctors select the most suitable medication or therapy and administer it using the proper dose or regimen. Personalized medicine is being advanced through data from the Human Genome Project, which provides insights into individual genetic differences and allows for tailored predictions about disease risk and drug responses. This approach is moving healthcare from a reactive to a preventive model, enabling better disease detection, customized prevention strategies, and more effective treatments. It also has the potential to reduce the time, cost, and failure rate of pharmaceutical clinical trials and eliminate trial-and-error inefficiencies that inflate healthcare costs. Precision medicine is a data-driven approach that takes into account a person's medical genome, lifestyle, and other information, supporting the development of unique drugs that target specific patients. [13]

Drug Design and Optimization:
AI can assist in the design of novel drug molecules with desirable properties, such as improved efficacy and reduced toxicity. By generating and evaluating virtual compound libraries, AI algorithms can suggest modifications to existing molecules or propose entirely new structures that are optimized for specific targets. Drug design and optimization involve the use of computational techniques to identify and optimize potential drug candidates. Artificial intelligence (AI) plays a significant role in this process, enabling the efficient design and optimization of drug molecules. AI algorithms can analyze vast biological data, including genomics and proteomics, to identify disease-associated targets and predict their interactions with potential drug candidates, enabling a more efficient and targeted approach to drug discovery. AI techniques such as machine learning from genomics and bioinformatics data, and mining of electronic medical records (EMR) and claims data can be deployed to cover everything from drug to protein interactions at the molecular level to sifting through millions of records to find existing drugs used to treat other conditions. AI-powered drug design and optimization have several advantages, including reducing time and cost in drug development, improving the accuracy of the method, and enabling a more productive approach in identifying new therapeutic uses for existing drugs. The use of AI in drug design and optimization is expanding rapidly, with several research groups and labs focusing on this area. [12]

AI Essential for Auxiliary Medication Screening

Absolutely, AI is essential for auxiliary medication screening in several ways:

- Efficiency: AI algorithms can quickly analyze vast amounts of biomedical data, including information on drug compounds, molecular structures, and biological pathways. This enables researchers to screen a large number of potential medications much more efficiently than traditional methods.
- Precision: AI can identify subtle patterns and relationships within complex datasets that may not be apparent to human researchers. This precision allows for the identification of promising drug candidates with specific mechanisms of action or target profiles.
- Cost-Effectiveness: By automating the screening process, AI can significantly reduce the time and resources required for medication discovery. This can lower the overall cost of drug development and make it more accessible to researchers and pharmaceutical companies.
- Personalized Screening: AI can analyze individual patient data to identify medications that are most likely to be effective for specific conditions or genetic profiles. This personalized approach to medication screening has the potential to improve patient outcomes and minimize adverse reactions.
- Drug Repurposing: AI algorithms can sift through existing medications to identify potential new uses for them. This approach to drug repurposing can expedite the development of treatments for new indications by leveraging existing safety and efficacy data. Artificial intelligence applications in the drug development process. [30]

Artificial Intelligence Application in the Drug Development Process

Artificial intelligence (AI) has significantly impacted the pharmaceutical industry, particularly in drug discovery and development, revolutionizing various aspects of the sector. Here are key insights from recent articles on the application of AI in drug development:
AI Integration in Pharmaceutical Sector: AI has been instrumental in drug discovery, repurposing, improving productivity, and enhancing clinical trials
The use of AI tools and techniques has reduced human workload and accelerated target achievements in a short period
AI in Drug Discovery: AI can recognize hit and lead compounds, validate drug targets, and optimize drug structure design efficiently
Despite its advantages, AI faces challenges such as managing large volumes of diverse data sets in drug development
Clinical Relevance of AI: AI methods have improved various stages of drug development, including molecular design, structure-based drug design, and pre-clinical development
AI technologies empower researchers to analyze vast datasets with speed and precision, expediting early stages of drug discovery
Challenges and Future Prospects: While AI shows promise in accelerating drug discovery, its adoption comes with inherent risks that require careful consideration and validation
The integration of AI/ML technologies into drug development aims to revolutionize the field but necessitates addressing challenges for successful implementation [15]

CONCULSION

Artificial Intelligence (AI) holds tremendous potential to revolutionize drug management by enhancing drug research and development, repurposing, clinical trials, and prescription administration. Large data the quantities can be handled by AI with improved automation, which can assist in managing the clinical data gathered and using it for future drug research, as well as helping to determine the best course of treatment for a patient, including tailored medications. Through thorough market research and forecasting, AI can also help confirm the product's safety and effectiveness in clinical trials and guarantee appropriate pricing and positioning in the marketplace. Even though no medications have been created using AI-based methods to date, it is very possible that AI will

ultimately prove to be an extremely helpful instrument in the pharmaceutical sector, AI has the power to rush medication finding out, slash costs related to healthcare, as well as improve patient outcomes.

REFERENCES

1. Lipinski CF, Maltarollo VG, Oliveira PR et al (2019) Advances and perspectives in applying deep learning for drug design and discovery. Front Robot AI
2. 1348 Molecular Diversity (2021) 25:1315–13601 3 25. Fukushima K (1988) Neocognitron: a hierarchical neural network capable of visual pattern recognition. Neural Netw1 (2):119–130.
3. Hamet P, Tremblay J (2017) Artificial intelligence in medicine. Metabolism 2002
4. Hassanzadeh P, Atyabi F, Dinarvand R (2019) the significance of artificial intelligence in drug delivery system design. Adv Drug Deliv Rev 2019
5. Zhang L, Tan J, Han D, Zhu H (2017) from machine learning to deep learning: progress in machine intelligence for rational drug discovery. Drug Discov Today
6. Krikorian G., Torreele E. We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis. Health Hum. Rights. 2021; 23:119–127.
7. Mak K.-K., Pichika M.R. Artificial Intelligence in Drug Development: Present Status and Future Prospects. Drug Discov. Today. 2019;
8. Munos B. Lessons from 60 Years of Pharmaceutical Innovation. Nat. Rev. Drug Discov. 2009;
9. Chavda V., Valu D., Parikh P., Tiwari N., Chhipa A., Shukla S., Patel S., Balar P., Paiva-Santos A., Patravale V. Conventional and Novel Diagnostic Tools for the Diagnosis of Emerging SARS-CoV-2 Variants. Vaccines. 2023
10. Sharma R., Shishodia A., Gunasekaran A., Min H., Munim Z.H. The Role of Artificial Intelligence in Supply Chain Management: Mapping the Territory. Int. J. Prod. Res. 2022
11. Grilo A.L., Mantalaris A. The Increasingly Human and Profitable Monoclonal Antibody Market. Trends Biotechnol. 2019.
12. . Daka A., Peer D. RNAi-Based Nanomedicines for Targeted Personalized Therapy. Adv. Drug Deliv. Rev. 2012
13. Kalepu S., Nekkanti V. Insoluble Drug Delivery Strategies: Review of Recent Advances and Business Prospects. Acta Pharm. Sin. B. 2015
14. Dickherber A., Morris S.A., Grodzinski P. NCI Investment in Nanotechnology: Achievements and Challenges for the Future. Wiley Interdiscip. Rev. Nanomed. Nanobio Technol. 2015
15. National Nanotechnology Initiative NNI Budget Supplements and Strategic Plans. [(accessed on 1 May 2023)]
16. Hassanzadeh P., Atyabi F., Dinarvand R. The Significance of Artificial Intelligence in Drug Delivery System Design. Adv. Drug Deliv. Rev. 2019;151–152
17. Sacha G.M., Varona P. Artificial Intelligence in Nanotechnology. Nanotechnology. 2013
18. Wong W., Chee E., Li J., Wang X. Recurrent Neural Network-Based Model Predictive Control for Continuous Pharmaceutical Manufacturing. Mathematics. 2018
19. Wise J., Möller A., Christie D., Kalra D., Brodsky E., Georgieva E., Jones G., Smith I., Greiffenberg L., McCarthy M., et al. The Positive Impacts of Real-World Data on the Challenges Facing the Evolution of Biopharma. Drug Discov. Today. 2018
20. Taylor D., Bowden S.G., Knorr R., Wilson D.R., Proudfoot J., Dunlop A.E. The Pistoia Alliance Controlled Substance Compliance Service Project: From Start to Finish. Drug Discov. Today. 2015
21. Lee C.K.H., Choy K.L., Chan Y.N. A Knowledge-Based Ingredient Formulation System for Chemical Product Development in the Personal Care Industry. Comput. Chem. Eng. 2014
22. Schmidhuber J. Deep Learning in Neural Networks: An Overview. Neural Netw. 2015
23. Roboticsbiz Ai-in-Drug-Discovery-Benefits-Drawback-and-Challenges. [(accessed on 5 May 2023)
24. Sarker I.H. Machine Learning: Algorithms, Real-World Applications and Research Directions. SN Comput. Sci. 2021
25. Sarker I.H. AI-Based Modeling: Techniques, Applications and Research Issues towards Automation, Intelligent and Smart Systems. SN Comput. Sci. 2022
26. Kavasidis I., Lallas E., Gerogiannis V.C., Charitou T., Karageorgos A. Predictive Maintenance in Pharmaceutical Manufacturing Lines Using Deep Transformers. Procedia Comput. Sci. 2023
27. Bagherian M., Sabeti E., Wang K., Sartor M.A., Nikolovska-Coleska Z., Najarian K. Machine Learning Approaches and Databases for Prediction of Drug–Target Interaction: A Survey Paper. Brief. Bioinform. 2021
28. Kumar Y., Koul A., Singla R., Ijaz M.F. Artificial Intelligence in Disease Diagnosis: A Systematic Literature Review, Synthesizing Framework and Future Research Agenda. J. Ambient. Intell. Humaniz. Comput. 2023
29. Chapman A.B., Peterson K.S., Alba P.R., DuVall S.L., Patterson O.V. Detecting Adverse Drug Events with Rapidly Trained Classification Models. Drug Saf. 2019
30. Elkin M.E., Zhu X. Predictive Modeling of Clinical Trial Terminations Using Feature Engineering and Embedding Learning. Sci. Rep. 2021

31. Chavda V.P., Sorathiya A., Valu D., Marwadi S. Computation in BioInformatics: Multidisciplinary Applications. John Wiley & Sons; Hoboken, NJ, USA: 2021. Role of Data Mining in Bioinformatics; pp. 69–84.
32. Goldstein M., Uchida S. A Comparative Evaluation of Unsupervised Anomaly Detection Algorithms for Multivariate Data. PLoS ONE. 2016
33. Noguchi Y., Ueno A., Otsubo M., Katsuno H., Sugita I., Kanematsu Y., Yoshida A., Esaki H., Tachi T., Teramachi H. A New Search Method Using Association Rule Mining for Drug-Drug Interaction Based on Spontaneous Report System. Front. Pharmacol. 2018
34. . Liu L., Tang L., Dong W., Yao S., Zhou W. An Overview of Topic Modeling and Its Current Applications in Bioinformatics. SpringerPlus. 2016